Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 36 of 881 for:    "Reticulum Cell Sarcoma"

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + (Immuno ALCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02902874
Recruitment Status : Recruiting
First Posted : September 16, 2016
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary:
To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Condition or disease Intervention/treatment Phase
ALCL Other: Blood sample Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
Study Start Date : April 2010
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Patients treated for anaplastic large cell lymphoma ( ALCL ) Other: Blood sample



Primary Outcome Measures :
  1. Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology [ Time Frame: up to 78 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies
  • Clinical data registered in SFCE database
  • Signed consent form

Exclusion Criteria:

  • No ALK expression on tumour
  • No consent signed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02902874


Contacts
Layout table for location contacts
Contact: Minard Véronique, MD 0142114180 ext +33 veronique.minard@gustaveroussy.fr

Locations
Layout table for location information
France
Gustave Roussy Recruiting
Villejuif, Val De Marne, France, 94805
Contact: Minard Véronique, MD    0142114180 ext +33    veronique.minard@gustaveroussy.fr   
Sponsors and Collaborators
Gustave Roussy, Cancer Campus, Grand Paris

Layout table for additonal information
Responsible Party: Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov Identifier: NCT02902874     History of Changes
Other Study ID Numbers: 2009-A01343-54
2009/1603 ( Other Identifier: CSET Number )
First Posted: September 16, 2016    Key Record Dates
Last Update Posted: August 9, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Large-Cell, Anaplastic
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, T-Cell
Lymphoma, Non-Hodgkin